

# VEGA DAILY

Unlock Your Best Quote  
Ask VEGA Now!

June 2, 2026

## VITAMIN

01

- NHU recently obtained authorization for a new invention patent titled 'Method for Recovering and Reusing Ammonia and Acetylene from Acetylation Reaction Off-Gas', further strengthening its process innovation capabilities.
- DSM-Firmenich announced that its shares are now officially listed on the SIX Swiss Exchange under the ticker symbol DSFIR. The move establishes a dual listing alongside Euronext Amsterdam, expanding the company's access to global capital markets and supporting its long-term growth strategy.

## AMINO ACID

02

Meihua Biological, together with several research institutions, published a study in Nature Communications reporting a breakthrough in anaerobic L-valine fermentation. The technology has been successfully validated at industrial scale, achieving an L-valine titer of 83.6 g/L within 60 hours and a conversion efficiency of 85% of the theoretical yield, supporting more efficient and low-carbon L-valine production.

## API

03

- Apelo Pharmaceutical Co., Ltd. recently received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines (EDQM) for Amantadine Hydrochloride API.
- Florfenicol prices remained firm, supported by relatively high raw material costs. Market transactions continued to be driven by immediate demand, with current prices around RMB 165-170/KG.
- On May 27, CSPC Pharmaceutical Group reported Q1 2026 revenue of RMB 6.47 billion, down 7.8% year-on-year, while net profit attributable to shareholders fell 41.8% to RMB 860 million. The results reflect continued pressure on the company's traditional flagship products as industry competition and centralized procurement policies reshape the market landscape.

## FOOD ADDITIVE

04

Fonterra reported strong FY2026 third-quarter results, with operating profit increasing by NZD 103 million year-on-year to NZD 1.8 billion. Growth was primarily driven by sustained global demand for protein ingredients, particularly in the U.S. and European markets. CEO Richard Allen stated that the upgraded full-year earnings guidance reflects strong shipment expectations for the final quarter, while noting that ongoing geopolitical tensions in the Middle East continue to create uncertainty for global markets.

Reported by Candice, Shea and Sharon

ONE STOP SOLUTION SUPPLIER

**VEGA**

[www.vegapharma.com](http://www.vegapharma.com)

**vegamax**

[www.vegafeed.com](http://www.vegafeed.com)

**Prumix**  
Ideas for better health

[www.prumix.com](http://www.prumix.com)

